Table 3.

Ongoing long-term prophylaxis medications for HAE reported in patients enrolled in IOS

Medication, n (%)	Spain n = 73	Other countries N = 385
Danazol	29 (39.7)	215 (55.8)
Stanozolol	32 (43.8)	19 (4.9)
Plasma-derived C1 inhibitora	21 (28.8)	87 (22.6)
Tranexamic acid	19 (26.0)	102 (26.5)
Oxandrolone	0	8 (2.1)
Recombinant C1 inhibitor	0	5 (1.3)
Other	5 (6.8)	47 (12.2)

All long-term prophylaxis medications reported at any time during follow-up in IOS are included in the summary; patients may be included in more than one category

HAE hereditary angioedema, IOS Icatibant Outcome Survey

^aIncludes Berinert®, Cinryze®, and unspecified C1 inhibitors